Analex Corp – ‘8-K’ for 12/20/01 – EX-99

On:  Friday, 12/21/01   ·   For:  12/20/01   ·   Accession #:  928385-1-502896   ·   File #:  0-05404

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         4      9K 
 2: EX-99       Miscellaneous Exhibit                                  2     13K 

EX-99   —   Miscellaneous Exhibit

EX-99
1st Page of 2
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
[HADRON LOGO APPEARS HERE]                                                      

                                               Release:      IMMEDIATE
                                                      For:      HADRON, INC.
                                                                  (Symbol: HDRN)

Contact:     Amber Gordon                                                       
(703) 329-9400                                        

Hadron Advanced Biosystems Announces
Research Plans and Product Development Strategies 
for Broad Defense against Biological Weapons

Alexandria, VA, December 20, 2001 -- Hadron, Inc. (OTC BB: HDRN) today publicly 
announced the biodefense research plans and product development strategies being
pursued by its Advanced Biosystems, Inc. subsidiary. This announcement is being 
made in response to the high level of public interest in biowarfare research    
following recent anthrax attacks.                                               

Dr. Ken Alibek, President of Hadron Advanced Biosystems, and Sterling 
Phillips, President and CEO of Hadron, outlined the Company's current research  
efforts in the field of methods for boosting non-specific immunity. The         
objective of these investigative efforts is to identify mechanisms by which the 
immune system may be temporarily boosted so as to provide short-term, enhanced  
immune responses to exposure to infectious agents, especially those that might  
be used as bioterrorist weapons. Upon the successful completion of these        
investigative efforts, Hadron Advanced Biosystems intends either to license its 
technology to, or seek a joint venture with, a partner to complete the necessary
clinical trials, regulatory approvals, and the development, manufacturing, and  
marketing of any future products which might arise from these efforts.          

 The Company has been involved in basic research in this field since May
2000, when it received its first contract award from the Defense Advanced       
Research Projects Agency (DARPA). To date, Hadron Advanced Biosystems has       
received $12 million in funding for medical biodefense research from DARPA, the 
United States Army Medical Research and Material Command and the National       
Institute of Health. Dr. Alibek has been a leader in the field of biowarfare    
agent experimentation and the treatment of diseases caused by biowarfare agents 
for more than 25 years.                                                         

  "The medical defenses under investigation are based on novel approaches,
developed in our labs, to the etiology and pathogenesis of the diseases caused  
by biological weapons," stated Dr. Alibek. Mr. Phillips commented, "In light of 
the intense media attention focused on bioterrorism, we believe it is helpful to
clarify Hadron's role in biodefense, and to explain the research in progress."  

                                                                       More...

EX-99
Last Page of 2
TOC
1st
Previous
Next
↓Bottom
Just 2nd
HDRN:  Announces Strategies for Broad Defense against Biological          Page 2
Weapons                                                           
December 20, 2001                                                               

Hadron Advanced Biosystems now has 35 scientists working on related   
experiments in its Manassas, Virginia laboratories. The labs are located within 
George Mason University's Prince William, Virginia campus. Initial in-vitro test
results have isolated immune-boosting compounds that Hadron Advanced Biosystems 
believes will protect animals exposed to a variety of biological agents. Further
animal testing is required to confirm initial results. The Company's            
investigations cover a wide variety of biological weapons threats, including    
methods of enhancing antibiotic therapies, strengthening the host immune        
response, and new methods for battling anthrax sepsis and septic shock. Other   
research areas include investigation of the effects of certain cytokine         
combinations, other natural and synthetic modulators of the innate immune       
response, computer modeling of cytokines and cytokine-receptors, and the        
construction of new peptides that mimic the effects of certain cytokines. Hadron
Advanced Biosystems plans to obtain new laboratory space during the next year in
order to begin in vivo testing.                                                 

  It is envisioned that the results of these experiments could lead to the
development of medications which would be inhaled, where the spray could provide
a boost of non-specific immunologic defenses, based on activation of mucousal   
immunity of the respiratory tract. Following a terrorist attack or contact with 
many biological agents used as weapons, it is hoped that people could use such a
spray before it was even known what specific biological agent had been involved.
It is envisioned that such a spray might boost the immune system to fight the   
biowarfare agent for a period of days or weeks.                                 

The Company envisions that any potential products would be developed, 
tested, approved by regulatory agencies, and marketed in partnership with       
another firm. The timeframe and the full cost of the effort have not yet been   
determined by the Company, but marketable products would most likely be several 
years away.                                                                     

   HADRON specializes in developing intelligence and biodefense solutions in
support of our Nation's security. Hadron focuses on developing innovative       
technical solutions for the intelligence community, analyzing and supporting    
defense systems and developing medical defenses and treatments for toxic agents 
used in biological warfare and terrorism. The Company's stock trades on the OTC 
Electronic Bulletin Board under the symbol HDRN. HADRON can be found on the     
Internet at http://www.hadron.com. HADRON investor relations can be contacted at
---------------------                                   
(703) 329-9400 x311 or via email at agordon@hadron.com.                         
          ------------------

Except for the historical information contained herein, this press release      
contains forward-looking statements within the meaning of Section 21E of the    
Securities and Exchange Act of 1934, as amended, that involve a number of risks 
and uncertainties. These forward-looking statements may be identified by        
reference to a future period by use of forward-looking terminology such as      
"anticipate," "expect," "could," "would," "envisioned," "intend," "may" and     
other words of a similar nature. There are certain important factors and risks  
that could cause results to differ materially from those anticipated by the     
statements contained herein. Such factors and risks include business conditions 
and growth in the medical research, government contracting and pharmaceutical   
arenas, and in the economy in general, as well as scientific and technical risks
associated with research and development activities. Competitive factors include
the pressures toward consolidation of small government contracts into larger    
contracts awarded to major, multi-national corporations; and the Company's      
ability to continue to recruit and retain highly skilled scientific, technical, 
managerial and sales/marketing personnel. Other risks may be detailed from time 
to time in the Company's filings with the Securities and Exchange Commission.   
Hadron undertakes no obligations to update or revise any forward-looking        
statements, whether as a result of new information, future events or otherwise. 

# # # 

Dates Referenced Herein

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		12/21/01							None on these Dates
For Period End:		12/20/01		1		2
									List all Filings